Choksi Laboratories confirmed its 33rd Annual General Meeting (AGM) will be held on September 18, 2026. The company has also dispatched physical letters to shareholders who have not registered their email addresses, providing direct web links to access the annual report and AGM notice.

The communication, issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, clarifies that while electronic copies of the FY26 annual report were sent to registered members, those without valid emails received physical intimation. This ensures compliance with Regulation 36(1)(b), which mandates alternative communication methods for unregistered shareholders.

Financial Performance

Choksi Laboratories reported a 29% increase in net profit after tax (PAT) to ₹196.43 lakh for FY26, compared to ₹152.33 lakh in the previous year. The growth was supported by a 10.4% rise in total revenue to ₹4,621.93 lakh and an exceptional gain of ₹75.30 lakh from the sale of a Mumbai property.

The company issued its 33rd Annual Report and AGM notice on August 25, 2026, confirming the meeting date as September 18, 2026. This corrects the previously communicated date of August 21, 2026. The meeting will be conducted via Video Conferencing or Other Audio Visual Means, with the registered office in Indore serving as the deemed venue.

Revenue from operations stood at ₹4,600.59 lakh in FY26, up from ₹4,178.23 lakh in FY25. Profit before tax (PBT) was ₹319.46 lakh, including the exceptional item. Excluding this one-time gain, operational PBT was ₹244.16 lakh, compared to ₹215.33 lakh in FY25.

The improvement in financial performance was attributed to higher business volumes, better operational efficiencies, and effective resource utilization. No dividend was recommended for the year due to fund requirements for operations.

Key Operational Developments

The company faced a ransomware cyberattack on May 22, 2025, which temporarily disrupted operations and access to financial data. Critical data was recovered by May 31, 2025, using secured off-site backups. The incident delayed the approval of audited results for Q4FY25 and FY25, leading to a penalty from the stock exchange for delayed disclosures. The company has since enhanced its cybersecurity protocols.

Additionally, Choksi Laboratories changed its Registrar and Share Transfer Agent from MUFG Intime Private Limited to Ankit Consultancy Private Limited, effective August 3, 2026.

Agenda Items

Shareholders will transact the following business at the AGM:

• Approve audited financial results for the year ended March 31, 2026.
• Reappoint Mr. Sunil Choksi as a director, who retires by rotation.
• Reappoint Ms. Himika Choksi as a Whole-Time Director for five years.

Key Dates

The register of members will remain closed from September 11, 2026, to September 18, 2026.

Director Reappointment Details

The board seeks approval for the reappointment of Ms. Himika Choksi as Whole-Time Director from April 1, 2027, to March 31, 2032. Her monthly salary is set between ₹4,00,000 and ₹5,00,000, subject to annual increments of ₹25,000.

Prakhar Dubey, Company Secretary and Compliance Officer, signed the communication addressed to the General Manager of the Corporate Relationship Department at The Bombay Stock Exchange Limited.

Choksi Laboratories received 4 observations from the US Food and Drug Administration following an inspection at its Indore facility.

USFDA inspection outcome

The USFDA conducted an inspection of Choksi Laboratories' Indore facility, at the conclusion of which the regulatory authority issued 4 observations to the company. Such observations are part of the standard post-inspection process under USFDA protocols, wherein inspectors document findings for the inspected site to address.

Companies typically respond to USFDA observations within a stipulated timeframe, outlining corrective and preventive actions for each point raised. No further details regarding the nature of the observations were disclosed in the available information.